PARP1/PRMT5-IN-1
PARP1/PRMT5-IN-1 is an inhibitor of PARP1 and PRMT5, with an IC50 of 0.60 nM against PARP1 and an IC50 of 4.67 nM against PRMT5. PARP1/PRMT5-IN-1 downregulates the homologous recombination (HR)-associated factors BRCA1, BRCA2, and RAD51, thereby suppressing homologous recombination function. PARP1/PRMT5-IN-1 induces the accumulation of DNA double-strand breaks. PARP1/PRMT5-IN-1 triggers apoptosis. PARP1/PRMT5-IN-1 is applicable for breast cancer research.
For research use only. We do not sell to patients.
- CAS No.: 3133817-84-9
- Formula: C41H43FN8O4
- Molecular Weight:730.83
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Histone Methyltransferase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
PARP1 0.60 nM (IC50) |
PRMT5 4.67 nM (IC50) |
BRCA1 |
BRCA2 |
RAD51 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDA-MB-436 | IC50 |
0.76 μM
|
Antiproliferative activity against human MDA-MB-436 breast cancer cells assessed by MTT assay after 7 days of incubation.
Antiproliferative activity against human MDA-MB-436 breast cancer cells assessed by MTT assay after 7 days of incubation.
|
42607456 |
| MDA-MB-468 | IC50 |
0.48 μM
|
Antiproliferative activity against human MDA-MB-468 breast cancer cells assessed by MTT assay after 7 days of incubation.
Antiproliferative activity against human MDA-MB-468 breast cancer cells assessed by MTT assay after 7 days of incubation.
|
42607456 |
| MDA-MB-231 | IC50 |
0.29 μM
|
Antiproliferative activity against human MDA-MB-231 breast cancer cells assessed by MTT assay after 7 days of incubation.
Antiproliferative activity against human MDA-MB-231 breast cancer cells assessed by MTT assay after 7 days of incubation.
|
42607456 |
| MCF7 | IC50 |
0.27 μM
|
Antiproliferative activity against human MCF-7 breast cancer cells assessed by MTT assay after 7 days of incubation.
Antiproliferative activity against human MCF-7 breast cancer cells assessed by MTT assay after 7 days of incubation.
|
42607456 |
In Vitro
PARP1/PRMT5-IN-1 exerts potent dual nanomolar inhibitory activity against purified recombinant PARP1 and PRMT5 enzymes[1].
PARP1/PRMT5-IN-1 exhibits high selectivity for PARP1/PARP2 and PRMT5 over closely related PARP and PRMT family isoforms[1].
PARP1/PRMT5-IN-1 (30 μM; 4 h) directly and potently binds to both endogenous PARP1 and PRMT5 proteins in intact MDA-MB-231 breast cancer cells[1].
PARP1/PRMT5-IN-1 (0.3-3 μM; 5 days) effectively suppresses the catalytic activity of both PARP1 and PRMT5 in living MDA-MB-231 cells without affecting total protein expression levels of the two targets, and does not interfere with type I PRMT enzyme activity[1].
PARP1/PRMT5-IN-1 (compound 8I) (7 days) exerts potent antiproliferative effects independent of BRCA mutational status across both BRCA-mutant MDA-MB-436 and BRCA wild-type MDA-MB-468, MDA-MB-231, and MCF-7 human breast cancer cell lines[1].
PARP1/PRMT5-IN-1 (0.3-1 μM; 12 days) exerts superior long-term antiproliferative and colony-suppressive effects in BRCA wild-type MDA-MB-231 breast cancer cells relative to single-agent PARP1 or PRMT5 inhibitors[1].
PARP1/PRMT5-IN-1 (1-3 μM; 5 days) induces prominent double-strand DNA damage and suppresses homologous recombination via reduction of RAD51 foci formation in MDA-MB-231 breast cancer cells[1].
PARP1/PRMT5-IN-1 (1-3 μM; 5 days) induces higher levels of accumulated DNA break damage in MDA-MB-231 breast cancer cells than treatment with single-agent PARP1 inhibition, single-agent PRMT5 inhibition, or their combination[1].
PARP1/PRMT5-IN-1 (3 μM; 5 days) induces synergistic dual S and G2/M phase cell cycle arrest in MDA-MB-231 breast cancer cells[1].
PARP1/PRMT5-IN-1 (3 μM; 5 days) induces robust apoptotic cell death in MDA-MB-231 breast cancer cells that is greater than the apoptosis induced by single-agent PARP1 or PRMT5 inhibition or their combination[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-231 breast cancer cells
-
Concentration:30 μM
-
Incubation Time:4 h
-
Result:Directly and potently binded to endogenous PARP1 and PRMT5 proteins in intact MDA-MB-231 breast cancer cells.
-
Cell Line:MDA-MB-231 human breast cancer cells
-
Concentration:0.3 μM; 1 μM; 3 μM
-
Incubation Time:5 days
-
Result:Did not alter total PARP1 or PRMT5 protein expression levels.
Effectively reduced the cellular levels of poly ADP-ribose (p-ADPr), histone H4 symmetric dimethylarginine at residue 3 (H4R3me2s), and global symmetric dimethylarginine (SDMA).
Did not cause any change in the levels of asymmetric dimethylarginine (ADMA).
-
Cell Line:MDA-MB-231 human breast cancer cells
-
Concentration:3 μM
-
Incubation Time:5 days
-
Result:Led to significant concurrent accumulation of cells in both S phase and G2/M phase, producing a synergistic cell cycle arrest effect that combined the separate S phase arrest induced by Olaparib (HY-10162) and G2/M phase arrest induced by GSK3326595 (HY-101563).
-
Cell Line:MDA-MB-231 human breast cancer cells
-
Concentration:3 μM
-
Incubation Time:5 days
-
Result:Effectively induced apoptosis in MDA-MB-231 cells, producing an apoptosis rate of 20.15%.
This apoptosis rate was higher than the rates of 6.09% achieved by Olaparib alone, 7.43% achieved by GSK3326595 alone, and 10.48% achieved by the combination of the two single agents.
-
Cell Line:MDA-MB-231 human breast cancer cells
-
Concentration:1 μM; 3 μM
-
Incubation Time:5 days
-
Result:Significantly induced the formation of nuclear γH2AX foci (a marker of DNA double-strand breaks) while markedly decreasing the number of nuclear RAD51 foci (a marker of active homologous recombination repair), compared to treatment with Olaparib or GSK3326595 alone.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/C nude mice (Female, 4-5 weeks old)[1]
-
Dosage:40 mg/kg; 80 mg/kg
-
Administration:i.p.; once daily; 27 consecutive days
-
Result:Achieved tumor growth inhibition (TGI) rate of 44% at 40 mg/kg/day.
Achieved tumor growth inhibition (TGI) rate of 79% at 80 mg/kg/day.
Showed no obvious body weight loss across all groups.
Upregulated the expression of DNA damage marker γH2AX in excised tumors.
Downregulated the proliferation marker Ki-67 in excised tumors.
Did not induce remarkable alterations in the cellular morphology or tissue structure of the heart, liver, spleen, lungs, and kidneys after 27 days of continuous administration.
Chemical Information
-
CAS No. 3133817-84-9
-
Molecular Weight 730.83
-
Formula C41H43FN8O4
-
SMILES
O=C1NN=C(CC2=CC(C(N3CCC4(CC(NC5=NC=NC(C(NC[C@H](O)CN6CCC(C=CC=C7)=C7C6)=O)=C5)C4)CC3)=O)=C(F)C=C2)C8=CC=CC=C81
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
CRISPR-Cas9 HDR knock-in/precise editing
CRISPR-Cas9 HDR knock-in uses a guide RNA to direct Cas9 to a genomic target adjacent to a PAM, where Cas9 creates a double-strand break; if a donor DNA template with homology to the cut region is present, cellular HDR can copy the donor sequence into the genome, producing a precise substitution, tag, reporter, or insertion rather than an indel. The readout is the fraction of alleles or cells carrying the intended donor-derived edit, measured by junction PCR, restriction-fragment analysis, Sanger sequencing, amplicon deep sequencing, flow cytometry for reporter knock-in, or clone genotyping; NHEJ indels and partial or non-HDR insertions are measured in parallel because they compete with or confound precise HDR outcomes.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)